ML351 is primarily investigated for its potential therapeutic applications, particularly in the field of inflammation and related disorders. It functions as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of anti-inflammatory and vasoprotective epoxyeicosatrienoic acids (EETs). By inhibiting sEH, ML351 helps to maintain higher levels of EETs, which can reduce inflammation, lower blood pressure, and protect against vascular damage. This makes it a promising candidate for the treatment of cardiovascular diseases, chronic inflammatory conditions, and potentially neuroinflammatory disorders. Research is ongoing to explore its efficacy and safety in preclinical and clinical settings.